FDA Issues Warning Letter to BMC Medical Over Unapproved CPAP Modifications and Failure to Report Firmware Glitches

The United States Food and Drug Administration (FDA) has officially issued a formal warning letter to Beijing-based medical device manufacturer BMC Medical Co Ltd, citing significant regulatory violations involving the unauthorized modification of sleep apnea therapy devices and a failure to report critical firmware corrections. The enforcement action follows a comprehensive inspection of the facilities belonging to React Health Inc, formerly known as 3B Medical Inc, which serves as the primary importer and distributor for BMC Medical products in the United States. The regulatory scrutiny centers on the company’s line of Continuous Positive Airway Pressure (CPAP) and Auto-adjusting Positive Airway Pressure (APAP) systems, which are vital for millions of patients suffering from obstructive sleep apnea (OSA).

According to the FDA’s findings, BMC Medical introduced modified versions of its respiratory devices into the American market without obtaining the necessary premarket notifications, commonly known as 510(k) clearances. This omission has led the agency to classify the affected devices as "adulterated" and "misbranded" under the Federal Food, Drug, and Cosmetic Act. Furthermore, the agency highlighted a lapse in mandatory safety reporting regarding a firmware glitch that caused devices to shut down unexpectedly during patient use, potentially posing a direct risk to user health and therapeutic efficacy.

Background of the Inspection and Regulatory Findings

The path to the warning letter began in December 2025, when FDA investigators conducted an on-site inspection of React Health’s facility located in Dublin, Ohio. During this inspection, the FDA clarified the corporate relationship and regulatory responsibilities between the two entities, determining that Beijing-based BMC Medical Co Ltd acts as the specification developer and the legal owner of the 510(k) clearances, while React Health manages the domestic distribution.

The core of the FDA’s grievance involves the G3X APAP device. The agency asserts that BMC Medical made substantial changes to the Luna CPAP and Auto CPAP System—a product line originally cleared for sale in 2016—resulting in the creation of a fundamentally new model, the G3X. Under federal law, if a manufacturer makes a "significant change or modification in design, components, method of manufacture, or intended use" that could affect the safety or effectiveness of a device, a new 510(k) submission is required. The FDA maintains that BMC Medical failed to fulfill this obligation before marketing the G3X APAP in the United States.

Technical Modifications and Safety Concerns

The FDA’s warning letter, dated May 20, 2026, meticulously outlines the specific technical and material changes that triggered the regulatory intervention. These modifications span software algorithms, hardware components, and physical materials, each of which the agency deems significant enough to require independent validation and regulatory review.

Algorithm and Software Enhancements

One of the primary concerns involves updates to the device’s firmware and software. BMC Medical introduced new recognition features designed to detect flow limitation, respiratory effort-related arousals (RERAs), and periodic breathing. These updates were intended to help the device distinguish between central hypopnea and obstructive hypopnea events. While such features are technologically advanced, the FDA notes that these algorithm changes directly impact how respiratory events are classified and how therapy is delivered. Without FDA review, there is no verified assurance that these algorithms are accurate or that they do not inadvertently provide sub-optimal pressure to the patient.

Material Changes to the Gas Pathway

Perhaps more concerning to regulatory experts is the modification of the device’s sound abatement system. The FDA found that the materials used in the sound-dampening components of the cleared Luna APAP were altered. Because these materials are located within the "gas pathway"—the channel through which air is pumped into a patient’s lungs—any change in material raises serious biocompatibility concerns. In recent years, the CPAP industry has been rocked by high-profile recalls related to the degradation of sound-abatement foam, which could release toxic gases or particulates. The FDA’s emphasis on this material change suggests a heightened sensitivity to any modifications that could affect the air quality delivered to users.

Hardware and Circuitry Updates

The agency also identified changes to the Printed Circuit Board Assembly (PCBA). Specifically, BMC Medical integrated a new chip designed to handle the increased processing demands of the new algorithms. The FDA argues that the combination of new processing hardware and new software creates a device that is functionally distinct from the version cleared in 2016, necessitating a fresh evaluation of its electrical safety and performance reliability.

Failure to Report Firmware Corrections

In addition to the unapproved modifications, BMC Medical was cited for a significant reporting violation regarding a known device malfunction. The FDA discovered that Luna G3 APAP devices running firmware version G3-2.00.76 were susceptible to "unexpected shutdowns" during use. For a patient with sleep apnea, an unexpected shutdown of a CPAP machine is not merely a technical inconvenience; it can lead to immediate respiratory distress, CO2 rebreathing, and a total loss of the intended therapy.

The FDA’s investigation revealed that BMC Medical was aware of the issue and had developed a remedy in the form of a firmware update (version G3-2.00.77). However, the company failed to report this "medical device correction" to the FDA within the mandatory 10-day window. Under 21 CFR Part 806, manufacturers are required to notify the agency of any action taken to reduce a risk to health posed by a device. As of May 19, 2026, just one day before the warning letter was issued, the FDA noted it still had not received the required formal report.

Chronology of Events

The timeline of the FDA’s interaction with BMC Medical and React Health underscores a period of several months during which the agency sought to bring the companies into compliance:

• 2016: BMC Medical receives original 510(k) clearance for the Luna CPAP and Auto CPAP System.
• December 2025: FDA inspectors visit React Health’s Dublin, Ohio, facility. They identify that the G3X models being sold differ significantly from the 2016 cleared designs.
• Early 2026: BMC Medical identifies a firmware bug (v. G3-2.00.76) causing shutdowns and begins deploying a fix (v. G3-2.00.77) to customers.
• May 19, 2026: The deadline passes for BMC Medical to have reported the firmware correction as a health-risk mitigation strategy.
• May 20, 2026: The FDA officially issues the warning letter to BMC Medical, citing unapproved modifications and reporting failures.

Market Context and Industry Implications

The warning letter comes at a sensitive time for the global sleep therapy market. Following the massive 2021 recall by Philips Respironics, which sidelined millions of devices due to foam degradation issues, smaller manufacturers like BMC Medical and distributors like React Health (formerly 3B Medical) saw a significant surge in market share. As healthcare providers and patients scrambled to find alternatives to Philips machines, BMC’s Luna series became a popular choice in the United States.

However, this increased market presence has brought with it increased regulatory oversight. The FDA has signaled that it will no longer tolerate "feature creep"—the practice of slowly adding new features to a device without updating regulatory filings. The emphasis on biocompatibility in the sound abatement system also reflects a post-Philips regulatory environment where the safety of the air pathway is a top priority.

For BMC Medical and React Health, the implications of this warning letter are severe. If the companies do not satisfy the FDA’s requirements, the agency has the authority to take further enforcement actions. These could include:

1. Import Bans: Blocking BMC Medical products from entering the United States.
2. Seizures: Physically taking possession of adulterated devices currently in domestic warehouses.
3. Injunctions: Seeking a court order to stop the sale of the devices.
4. Civil Money Penalties: Imposing significant fines for each day the violations persist.

Official Responses and Next Steps

The FDA has demanded that BMC Medical cease any activities that result in the misbranding or adulteration of their devices. The company was given 15 business days from the receipt of the letter to provide a written response detailing the specific steps taken to correct the violations and prevent their recurrence. This response must include a plan for how BMC Medical will handle the devices already in the hands of consumers and healthcare providers.

As of the current reporting, neither React Health nor BMC Medical has issued a public statement or responded to inquiries regarding the warning letter. The lack of comment has left many in the sleep medicine community—including durable medical equipment (DME) providers and sleep technicians—waiting for guidance on whether they should continue dispensing the G3X APAP model.

Analysis of Impact on Patients and Providers

For the thousands of patients currently using BMC Medical devices, the warning letter creates a period of uncertainty. While the FDA has not yet issued a formal recall of the G3X APAP, the classification of the device as "adulterated" suggests that its safety and effectiveness have not been legally established to the agency’s satisfaction.

Physicians and sleep clinics are now faced with a clinical dilemma. If a patient is successfully using a G3X device, the risk of discontinuing therapy may be higher than the risk posed by the unapproved modifications. However, the "unexpected shutdown" issue is a critical safety concern that must be addressed. Providers are encouraged to check the firmware versions of their patients’ devices to ensure they have been updated to version G3-2.00.77 or higher.

From a broader industry perspective, this case serves as a stern reminder to medical device manufacturers that the FDA’s 510(k) process is not a one-time hurdle but a continuous obligation. As digital health and algorithm-driven therapy become the norm, the line between a "minor update" and a "significant modification" has become a central battleground for regulatory compliance. The FDA’s action against BMC Medical highlights that even well-intentioned improvements to patient care—such as better detection of central sleep apnea—must be proven through the proper legal channels before they can be deployed in the American healthcare system.